Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genprex, Inc. (NASDAQ: GNPX).

Full DD Report for GNPX

You must become a subscriber to view this report.


Recent News from (NASDAQ: GNPX)

Genprex to Present at the 11th Annual LD Micro Main Event
Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney...
Source: Business Wire
Date: December, 03 2018 08:30
Genprex reports Q3 results
Genprex (NASDAQ: GNPX ): Q3 GAAP EPS of -$0.15. More news on: Genprex, Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 20 2018 08:40
Genprex Provides Clinical and Corporate Update for Third Quarter 2018
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30,...
Source: Business Wire
Date: November, 20 2018 08:30
Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations
Genprex, Inc. (NASDAQ:GNPX) , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this rol...
Source: Business Wire
Date: October, 30 2018 08:00
Genprex(TM) Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program
Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel pr...
Source: Business Wire
Date: September, 27 2018 08:00
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
Genprex amends options to license additional cancer fighting technologies from the University of Texas MD Anderson Cancer Center
Genprex (NASDAQ: GNPX ) has entered into amendments with The University of Texas MD Anderson Cancer Center to extend the terms of two option agreements pertaining the use of TUSC2, the active agent in Genprex’s Oncoprex, in combination with immunotherapies and the developm...
Source: SeekingAlpha
Date: August, 28 2018 08:56
Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to e...
Source: Business Wire
Date: August, 28 2018 08:30
Genprex to Present at Upcoming Investor Conferences
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company management will present at the following upcoming investor and industry conferences: About ...
Source: Business Wire
Date: August, 21 2018 08:30
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.252.372.42992.2530,524
2018-05-1711.9011.5912.668610.56264,716

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13609246.4935Cover
2018-12-121,8411,99792.1883Short
2018-12-111,6022,65260.4072Short
2018-12-101,9002,00095.0000Short
2018-12-073,8104,11392.6331Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNPX.


About Genprex, Inc. (NASDAQ: GNPX)

Logo for Genprex, Inc. (NASDAQ: GNPX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: GNPX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: April, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018
      Notification that form 10-K will be submitted late
      Filing Type: NT 10-KFiling Source: edgar
      Filing Date: April, 03 2018
      Post-effective amendment filed solely to add exhibits to a registration statement
      Filing Type: POS EXFiling Source: edgar
      Filing Date: March, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: GNPX)

      Daily Technical Chart for (NASDAQ: GNPX)


      Stay tuned for daily updates and more on (NASDAQ: GNPX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: GNPX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNPX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GNPX and does not buy, sell, or trade any shares of GNPX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/